Literature DB >> 32597817

Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?

Valentina Leta1,2, Daniel J van Wamelen1,2,3, Anna Sauerbier1,2,4, Shelley Jones1,2, Miriam Parry1,2, Alexandra Rizos1,2, K Ray Chaudhuri1,2.   

Abstract

Combined catechol-O-methyl-transferase-inhibition and Levodopa-Carbidopa intestinal gel (LCIG) infusion has the potential to reduce LCIG daily dose and the costs of this therapy. In this retrospective analysis, we report on Parkinson's disease (PD) patients on LCIG with concomitant Opicapone. In 11 patients, the introduction of Opicapone led to LCIG daily dose being reduced by 24.8% (p = 0.05) without any significant worsening of dyskinesia. Three patients withdrew from Opicapone due to side effects or inefficacy. LCIG daily dose reduction could lead to cost savings of £142,820.63/year in the United Kingdom while maintaining clinical care.

Entities:  

Keywords:  Catechol-O-methyl-transferase-inhibitor; Levodopa-Carbidopa intestinal gel; Opicapone; cost savings; intrajejunal Levodopa infusion

Year:  2020        PMID： 32597817     DOI： 10.3233/JPD-202022

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN： 1877-7171            Impact factor:   5.568


  6 in total

Review 1.  COMT Inhibitors in the Management of Parkinson's Disease.

Authors:  Margherita Fabbri; Joaquim J Ferreira; Olivier Rascol
Journal:  CNS Drugs       Date:  2022-02-25       Impact factor: 5.749

Review 2.  Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance.

Authors:  Dag Nyholm; Wolfgang H Jost
Journal:  Ther Adv Neurol Disord       Date:  2022-06-26       Impact factor: 6.430

Review 3.  Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.

Authors:  Vanessa Raeder; Iro Boura; Valentina Leta; Peter Jenner; Heinz Reichmann; Claudia Trenkwalder; Lisa Klingelhoefer; K Ray Chaudhuri
Journal:  CNS Drugs       Date:  2021-02-09       Impact factor: 5.749

4.  The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.

Authors:  K Ray Chaudhuri; A Simon Pickard; Ali Alobaidi; Yash J Jalundhwala; Prasanna L Kandukuri; Yanjun Bao; Julia Sus; Glynn Jones; Christian Ridley; Julia Oddsdottir; Seyavash Najle-Rahim; Matthew Madin-Warburton; Weiwei Xu; Anette Schrag
Journal:  Pharmacoeconomics       Date:  2022-03-21       Impact factor: 4.558

5.  Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.

Authors:  Yue Hui Lau; Valentina Leta; Katarina Rukavina; Miriam Parry; Jenny Ann Natividad; Vinod Metta; Guy Chung-Faye; K Ray Chaudhuri
Journal:  J Neural Transm (Vienna)       Date:  2022-05-03       Impact factor: 3.850

6.  Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.

Authors:  Katarzyna Smilowska; Daniel J van Wamelen; Tomasz Pietrzykowski; Alexander Calvano; Carmen Rodriguez-Blazquez; Pablo Martinez-Martin; Per Odin; K Ray Chaudhuri
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.